Archive
Past newsletters of MDDR.
Loading the archive
Past newsletters of MDDR.
Past newsletters of MDDR.
Friday, 10 July 2026
The Australian Institute of Health and Welfare (AIHW) emphasises the need for better data coordination in general practice to address the si
Thursday, 9 July 2026
The Pharmaceutical Benefits Advisory Committee has revoked special dispensation allowing GPs to initiate PBS-eligible adrenaline prescriptio
Wednesday, 8 July 2026
Two non-invasive tests have been recommended by the National Institute for Health and Care Excellence (NICE) to expedite the diagnosis of en
Tuesday, 7 July 2026
A new report from the Sax Institute reveals significant uncertainties regarding the evidence supporting pharmacist-led prescribing in Austra
Monday, 6 July 2026
The authors of a correspondence in The Lancet address the proposal to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ova
Sunday, 5 July 2026
Helena J Teede and colleagues propose renaming polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) based on
Saturday, 4 July 2026
Indivior will withdraw Sublocade, a slow-release buprenorphine injection, from the PBS in January, citing a commercial decision. This move h
Friday, 3 July 2026
Registered nurse prescribers in Australia gained the authority to prescribe Pharmaceutical Benefits Scheme (PBS) medicines, marking a signif
Thursday, 2 July 2026
The Minns government in New South Wales has proposed new driving laws for patients using THC-containing medicinal cannabis products. The Bil
Wednesday, 1 July 2026
The Australian Medical Association (AMA) has expressed strong opposition to the Pharmacy Board of Australia's draft prescribing endorsement